Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients

Table 1

Baseline characteristics of the patients in the study.

Variable	Total ()
Age, year (mean, SD)	45.6 (12.2)
Age group, (%)
≥60	35 (12.11)
<60	254 (87.99)
Gender, (%)
Male	204 (70.59)
Female	85 (29.41)
Weight loss, (%)
0–5 kg	221 (76.47)
5–10 kg	43 (14.88)
>10 kg	25 (8.65)
Smoking history, (%)
Yes	138 (47.75)
No	151 (52.25)
ECOG performance scale, (%)
0	40 (13.84)
1	238 (82.35)
2	11 (3.81)
WHO histopathologic grade, (%)
1	2 (0.69)
2	14 (4.84)
2–3	9 (3.11)
3	261 (90.31)
Unknown	3 (1.04)
Clinical stage, (%)
III	45(15.57)
IVA	156 (53.98)
IVB	88 (30.45)
T, (%)
T1-T3	74 (25.61)
T4	215 (74.39)
N, (%)
N0	25 (8.65)
N1	44 (15.22)
N2	131 (45.33)
N3a	131 (45.33)
N3b	64 (22.15)
Therapy, (%)	25 (8.65)
CCRT	201 (69.55)
NAC+CCRT	82 (28.37)
RT	6 (2.08)
RT cycle (fraction (median, min-max))	35 (15-39)
Total dose (Gy (median, min-max))	70 (30-78)
Overall time (days (median, min-max))	52 (23-97)
Chemosensitizer, (%)
<5 cycles	104 (35.99)
≥5 cycles	185 (64.01)
RT technique, (%)
2D/3DRCT	168 (58.13)
2D/3DRCT+IMRT	14 (4.84)
IMRT	104 (37.02)
Hemoglobin (g/l (median, min-max))	129 (68-167)
Platelet (×10^3/μl (median, min-max))	338 (113-801)
Transfusion on CCRT, (%)
Yes	124 (42.91)
No	165 (57.09)
3-year mortality, (%)
Yes	116 (40.14%)
No	149 (51.56%)
Lost to follow-up	24 (8.3%)

Notes: 2D: two dimensional; 3D-CRT: three-dimensional-conformal radiotherapy; CCRT: concurrent chemoradiotherapy; ECOG: Eastern Cooperative Oncology Group; IMRT: intensity-modulated radiotherapy; NAC: neoadjuvant chemotherapy; RT: radiotherapy; WHO: World Health Organization.